Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug299 | Anthocyanins Wiki | 0.33 |
| drug169 | AZD8154 Monodose DPI presented in capsules Wiki | 0.33 |
| drug171 | AZD8154 nebuliser Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug170 | AZD8154 Placebo Monodose DPI presented in capsules Wiki | 0.33 |
| drug3331 | Remote controlled exercise Wiki | 0.33 |
| drug165 | AZD1656 Wiki | 0.33 |
| drug1071 | Cooking Training Wiki | 0.33 |
| drug3896 | Table Setting Training Wiki | 0.33 |
| drug1303 | EG-HPCP-03a Wiki | 0.33 |
| drug1304 | EG-HPCP-03a Placebo Wiki | 0.33 |
| drug2443 | Multi-tasking Training Wiki | 0.33 |
| drug1746 | Home exercise Wiki | 0.24 |
| drug4025 | Tocilizumab Wiki | 0.11 |
| drug2365 | Methylprednisolone Wiki | 0.09 |
| drug3728 | Standard of Care Wiki | 0.05 |
| drug2916 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D030341 | Nidovirales Infections NIH | 0.24 |
| D060825 | Cognitive Dysfunction NIH | 0.17 |
| D003333 | Coronaviridae Infections NIH | 0.15 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012327 | RNA Virus Infections NIH | 0.14 |
| D003704 | Dementia NIH | 0.12 |
| D003324 | Coronary Artery Disease NIH | 0.11 |
| D011024 | Pneumonia, Viral NIH | 0.08 |
| D000860 | Hypoxia NIH | 0.07 |
| D012140 | Respiratory Tract Diseases NIH | 0.06 |
| D007249 | Inflammation NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| D055371 | Acute Lung Injury NIH | 0.06 |
| D012141 | Respiratory Tract Infections NIH | 0.05 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| D014777 | Virus Diseases NIH | 0.04 |
| D011014 | Pneumonia NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001268 | Mental deterioration HPO | 0.17 |
| HP:0000726 | Dementia HPO | 0.12 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.11 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012418 | Hypoxemia HPO | 0.07 |
| HP:0011947 | Respiratory tract infection HPO | 0.05 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 9 clinical trials
Background: There are no proven therapies specific for Covid-19. The full spectrum of Covid-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The efficacy of corticosteroids in viral ARDS remains controversial. Methods: This is an internationally (Spain, Canada, China, USA) designed multicenter, randomized, controlled, open-label clinical trial testing dexamethasone in mechanically ventilated adult patients with established moderate-to-severe ARDS caused by confirmed Covid-19 infection, admitted in a network of Spanish ICUs. Eligible patients will be randomly assigned to receive either dexamethasone plus standard intensive care, or standard intensive care alone. Patients in the dexamethasone group will receive an intravenous dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10. The primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free days at 28 days. All analyses will be done according to the intention-to-treat principle.
Description: All-cause mortality at 60 days after enrollment
Measure: 60-day mortality Time: 60 daysDescription: Number of ventilator-free days (VFDs) at Day 28 (defined as days being alive and free from mechanical ventilation at day 28 after enrollment, For patients ventilated 28 days or longer and for subjects who die, VFD is 0.
Measure: Ventilator-free days Time: 28 daysThe Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract. Most cases are mild or asymptomatic. However, around 5% of all patients develop Acute Respiratory Distress Syndrome (ARDS), which is the leading mortality cause in these patients. Corticosteroids have been tested in deferent scenarios of ARDS, including viral pneumonia, and the early use of dexamethasone is safe and appears to reduce the duration of mechanical ventilation in ARDS patients. Nevertheless, no large, randomized, controlled trial was performed evaluating the role of corticosteroids in patients with ARDS due SARS-CoV2 virus. Therefore, the present study will evaluate the effectiveness of dexamethasone compared to control (no corticosteroids) in patients with moderate and severe ARDS due to SARS-CoV2 virus.
Description: Ventilator-free days, defined as alive and free from mechanical ventilation, at 28 days after randomization.
Measure: Ventilator-free days Time: 28 days after randomizationDescription: Evaluation of the clinical status of patients on the 15th day after randomization defined by the 6-point Ordinal Scale, this scale ranges from 1 (Not hospitalized) to 6 (Death) with higher scores meaning worse outcomes.
Measure: Evaluation of the clinical status Time: 15 days after randomizationDescription: All-cause mortality rates at 28 days after randomization.
Measure: All-cause mortality Time: 28 days after randomizationDescription: Number of days of mechanical ventilation from randomization to day 28.
Measure: Mechanical ventilation duration Time: 28 days after randomizationDescription: Sequential Organ Failure Assessment (SOFA) Score 48 hours, 72 hours and 7 days after randomization
Measure: Sequential Organ Failure Assessment (SOFA) Score Time: Score at 48 hours, 72 hours and 7 days after randomizationDescription: Intensive Care Unit free days, defined as alive and discharged from the intensive care unit, at 28 days after randomization.
Measure: Intensive Care Unit free days Time: 28 days after randomizationThe investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Dexamethasone alone or Dexamethasone +Tocilizumab administration to patients enrolled in the CORIMUNO-19 cohort. Tocilizumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care (including Dexamethasone) treated patients
Description: Survival without needs of ventilator utilization (including non invasive ventilation and high flow) at day 14. Thus, events considered are needing ventilator utilization (including Non Invasive Ventilation, NIV or high flow), or death.
Measure: Survival without needs of ventilator utilization at day 14 Time: day 14Description: WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2>=150 OR SpO2/FIO2>=200: 7 Mechanical ventilation, (pO2/FIO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10
Measure: WHO progression scale at day 7 and 14 Time: day 7 and day 14Description: Overall survival
Measure: Overall survival at 14, 28, 60 and 90 days Time: 14, 28, 60 and 90 daysDescription: Cumulative incidence of discharge alive
Measure: Cumulative incidence of discharge alive at 14 and 28 days Time: 14 and 28 daysDescription: Survival without needs of mechanical ventilation at day 1. New DNR order (if given after the inclusion of the patient) will be considered as an event at the date of the DNR.
Measure: Survival without needs of mechanical ventilation at day 1 Time: day 1Description: Cumulative incidence of oxygen supply independency
Measure: Cumulative incidence of oxygen supply independency at 14 and 28 days Time: 14 and 28 daysA randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Description: The number of participants with "Clinical improvement" determined by the improvement of individual presenting symptoms of the COVID19; changes in radiological and laboratory values.Patient admitted in general bed requiring High Dependency Unit (HDU), and an HDU patient requiring Ventilator or Intensive care support.
Measure: Clinical improvement Time: Following randomization 30 days.Description: Oxygen saturation in the peripheral blood determined by pulse oximetry.
Measure: Changes in Oxygen level Time: Following randomization 30 days.We aim to assess the benefits and harms of higher (12 mg) vs lower doses (6 mg) of dexamethasone on patient-centered outcomes in patients with COVID-19 and severe hypoxia.
Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28
Measure: Days alive without life support at day 28 Time: Day 28 after randomisationDescription: Serious adverse reactions defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding or anaphylactic reaction
Measure: Number of participants with one or more serious adverse reactions Time: Day 28 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 28 Time: Day 28 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 90 Time: Day 90 after randomisationDescription: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90
Measure: Days alive without life support at day 90 Time: Day 90 after randomisationDescription: Number of days alive and out of hospital not limited to the index admission
Measure: Days alive and out of hospital at day 90 Time: Day 90 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 180 Time: Day 180 after randomisationDescription: Assessed by EQ-5D-5L
Measure: Health-related quality of life at day 180 Time: Day 180 after randomisationDescription: Assessed by EQ-VAS
Measure: Health-related quality of life at day 180 Time: Day 180 after randomisationrandomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19
Description: survival 14 days from admission date
Measure: Proportion of participants with Overall Survival at 14 days Time: 14 daysDescription: Change in Fio2/Pao2
Measure: Fio2/Pao2 Time: 2 daysBackground: There are no proven therapies specific for pulmonary dysfunction in patients with acute hypoxemic respiratory failure (AHRF) caused by infections (including Covid-19). The full spectrum of AHRF ranges from mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The efficacy of corticosteroids in AHRF and ARDS caused by infections remains controversial. Methods: This is a multicenter, randomized, controlled, open-label clinical trial testing dexamethasone in mechanically ventilated adult patients with established AHRF (including ARDS) caused by confirmed pulmonary or systemic infections, admitted in a network of Spanish ICUs. Eligible patients will be randomly assigned to receive dexamethasone: either 6 mg/d x 10 days or 20 mg/d x 5 days followed by 10 mg/d x 5 days. The primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free days at 28 days. All analyses will be done according to the intention-to-treat principle.
Description: All-cause mortality at 60 days after randomization
Measure: 60-day mortality Time: 60 daysDescription: Number of ventilator-free days (VFDs) at Day 28 (defined as days being alive and free from mechanical ventilation at day 28 after randomization. For patients ventilated 28 days or longer and for subjects who die, VFD is 0.
Measure: Ventilator-free days Time: 28 daysTo study signals of efficacy and safety of a currently available dosage form (IM) of EG-HPCP-03a in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
Description: Patients will be assessed for COVID-19 Ordinal Scale for Clinical Improvement scores and respiratory status throughout the study
Measure: The proportion of patients alive and without respiratory failure Time: First dose date to 28 days treatment dosing periodAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports